Literature DB >> 29897440

The Effect of Antibiotic Selection Pressure on the Nasopharyngeal Macrolide Resistome: A Cluster-randomized Trial.

Jeremy D Keenan1,2, Stephanie A Chin1, Abdou Amza3, Boubacar Kadri3, Baido Nassirou3, Vicky Cevallos1, Sun Y Cotter1, Zhaoxia Zhou1, Sheila K West4, Robin L Bailey5, Travis C Porco1,2,6, Thomas M Lietman1,2,6,7.   

Abstract

Background: Frequent use of antibiotics is thought to create selection pressure by clearing susceptible bacteria and allowing resistant bacteria to spread in a community. A cluster-randomized trial comparing 2 different frequencies of mass azithromycin distributions for trachoma provided a convenient experiment for determining the causal relationship between antibiotic consumption and antibiotic resistance.
Methods: Twenty-four communities were randomized to either annual or biannual mass azithromycin distributions for trachoma. Randomization was stratified on health catchment area and trachoma prevalence. Swabs were processed for the genetic macrolide resistance determinants ermB and mefA/E in a masked fashion from a random sample of 120 preschool children before treatment and another 120 children after 2 years of mass antibiotics.
Results: Macrolide resistance determinants were similar in the 12 annually and 12 biannually treated communities before treatment, with a median prevalence among preschool children of 20% (interquartile range [IQR], 10%-40%) in each group. By 24 months, macrolide resistance determinants were found more commonly in the biannually treated communities (median, 60% [IQR, 50%-80%]) than the annually treated communities (median, 40% [IQR, 20%-40%]; P < .001). Adjusting for baseline, the 24-month prevalence of macrolide resistance determinants in the biannual group was 29.4% higher than that of the annual group (95% confidence interval, 10.5%-56.7%). Conclusions: This randomized trial used direct genetic methods to confirm the causal relationship of community antibiotic consumption and antibiotic resistance. Communities randomized to less frequent use of antibiotics had a significantly lower prevalence of genetic antibiotic resistance determinants. Clinical Trials Registration: NCT00792922.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29897440     DOI: 10.1093/cid/ciy339

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  11 in total

1.  Antimicrobial Resistance Following Azithromycin Mass Drug Administration: Potential Surveillance Strategies to Assess Public Health Impact.

Authors:  Ines Mack; Mike Sharland; James A Berkley; Nigel Klein; Surbhi Malhotra-Kumar; Julia Bielicki
Journal:  Clin Infect Dis       Date:  2020-03-17       Impact factor: 9.079

2.  Effect of Azithromycin on the Ocular Surface Microbiome of Children in a High Prevalence Trachoma Area.

Authors:  Thuy Doan; Teshome Gebre; Berhan Ayele; Mulat Zerihun; Armin Hinterwirth; Lina Zhong; Cindi Chen; Kevin Ruder; Zhaoxia Zhou; Paul M Emerson; Travis C Porco; Jeremy D Keenan; Thomas M Lietman
Journal:  Cornea       Date:  2021-09-03       Impact factor: 3.152

3.  Antibiotics for trachoma.

Authors:  Jennifer R Evans; Anthony W Solomon; Rahul Kumar; Ángela Perez; Balendra P Singh; Rajat Mohan Srivastava; Emma Harding-Esch
Journal:  Cochrane Database Syst Rev       Date:  2019-09-26

4.  Antibacterial mass drug administration for child mortality reduction: Opportunities, concerns, and possible next steps.

Authors:  Isaac I Bogoch; Jürg Utzinger; Nathan C Lo; Jason R Andrews
Journal:  PLoS Negl Trop Dis       Date:  2019-05-23

5.  Impact of Intrapartum Oral Azithromycin on the Acquired Macrolide Resistome of Infants' Nasopharynx: A Randomized Controlled Trial.

Authors:  Abdoulie Bojang; Sarah L Baines; Bully Camara; Romain Guerillot; Liam Donovan; Raquel Sánchez Marqués; Ousman Secka; Umberto D'Alessandro; Christian Bottomley; Benjamin P Howden; Anna Roca
Journal:  Clin Infect Dis       Date:  2020-12-15       Impact factor: 9.079

6.  Rapid Changes in Nasopharyngeal Antibiotic Resistance Gene Profiles After Short Courses of Antibiotics in a Pilot Study of Ambulatory Young Children.

Authors:  Leigh M Howard; Keerti L Dantuluri; Nicole Soper; Isaac P Thomsen; Carlos G Grijalva
Journal:  Open Forum Infect Dis       Date:  2021-10-16       Impact factor: 3.835

7.  Mass drug administration with azithromycin for trachoma elimination and the population structure of Streptococcus pneumoniae in the nasopharynx.

Authors:  Rebecca A Gladstone; Ebrima Bojang; John Hart; Emma M Harding-Esch; David Mabey; Ansumana Sillah; Robin L Bailey; Sarah E Burr; Anna Roca; Stephen D Bentley; Martin J Holland
Journal:  Clin Microbiol Infect       Date:  2020-08-01       Impact factor: 8.067

8.  Serotype Profile of Nasopharyngeal Isolates of Streptococcus pneumoniae Obtained from Children in Burkina Faso before and after Mass Administration of Azithromycin.

Authors:  Soumeya Hema-Ouangraoua; Issaka Zongo; Nongodo Firmin Kabore; Nikiema Frédéric; Rakiswende Serge Yerbanga; Halidou Tinto; Yves Daniel Compaore; Irene Kuepfer; Daniel Chandramohan; Brian Greenwood; Jean Bosco Ouedraogo
Journal:  Am J Trop Med Hyg       Date:  2020-06-04       Impact factor: 2.345

9.  Impact of the addition of azithromycin to antimalarials used for seasonal malaria chemoprevention on antimicrobial resistance of Streptococcus pneumoniae.

Authors:  Soumeya Hema-Ouangraoua; Abdoul Aziz Maiga; Matthew Cairns; Issaka Zongo; Nikiema Frédéric; Rakiswendé Serge Yerbanga; Boubou Tamboura; Henry Badji; Georgia Gore-Langton; Irene Kuepfer; Halidou Tinto; Issaka Sagara; Alassane Dicko; Samba O Sow; Daniel Chandrahoman; Brian Greenwood; Jean Bosco Ouedraogo
Journal:  Trop Med Int Health       Date:  2019-11-13       Impact factor: 2.622

10.  Comparison of the Respiratory Resistomes and Microbiota in Children Receiving Short versus Standard Course Treatment for Community-Acquired Pneumonia.

Authors:  M M Pettigrew; J Kwon; J F Gent; Y Kong; M Wade; D J Williams; C B Creech; S Evans; Q Pan; E B Walter; J M Martin; J S Gerber; J G Newland; M E Hofto; M A Staat; V G Fowler; H F Chambers; W C Huskins
Journal:  mBio       Date:  2022-03-24       Impact factor: 7.786

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.